Paolo Paoletti

Paolo Paoletti is currently the CEO at GammaDelta Therapeutics, a biotech company focused on leveraging gamma delta T cells which are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathologies. He was formerly the first appointed president of GSK Oncology, where he was responsible for championing an organization of more than 2,000 professionals around the world dedicated to fighting the causes and impacts of cancer. During his tenure at GSK, seven new medicines to treat different kinds of cancer were approved globally, generating annual sales of about US$2 billion. In 2014, GSK sold the Oncology business for US$16 billion to Novartis in a complex three-way transaction.

Prior to joining GSK, Dr. Paoletti was Vice President of Oncology Clinical Research at Lilly, where he developed ALIMTA (> US$2 Billion annual sales). Most recently Dr. Paoletti was Chief Executive Officer of Kesios Therapeutics Limited. Dr. Paoletti is currently a non-executive director for Genmab, PsiOxus Therapeutics (Chairman of the Board), FORMA Therapeutics and Nucana Biomed. Dr. Paoletti has a degree in Medicine from the University of Pisa (Italy) where he was Professor in Pulmonary Diseases.